Description

Each Owens Peptide Solutions vial contains 20mg of lyophilized Retatrutide for qualified analytical and preclinical research. Also referenced in scientific literature as LY3437943, Retatrutide is a single-molecule agonist designed to interact with glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.

Research Use Disclaimer:

For laboratory and research use only. Not intended for human or animal consumption, medical use, diagnostic use, veterinary use, or therapeutic application.

Its combined receptor profile distinguishes it from compounds limited to one or two incretin-related pathways. Laboratory studies have used Retatrutide to examine receptor potency, glucose-responsive signaling, metabolic pathway coordination, energy expenditure models, and peptide pharmacology.

Current findings depend on the selected research system and should not be interpreted as confirmed therapeutic or clinical outcomes.